Gitanjali Srivastava: Where Medicine, AI, and Human-Centered Care Converge

 

Healthcare is entering an era in which treating disease increasingly depends on understanding the systems behind it. Few areas demonstrate this shift more clearly than obesity and metabolic health, where biology, technology, behavior, and access intersect. At the center of this evolving field is Gitanjali Srivastava, MD, MEng, Professor of Medicine, Pediatrics & Surgery and a global healthcare innovation executive whose work connects clinical medicine with engineering and artificial intelligence.

Recognized in The 2026 Power List: Leaders Driving Global Impact, Srivastava has built a career around challenging conventional assumptions about metabolic disease while developing approaches designed for increasingly personalized care.

From Curiosity to a Clinical Mission

Her interdisciplinary perspective has deep roots. Growing up in a family shaped by education, engineering, and scientific inquiry, she developed an early appreciation for mathematics, experimentation, and systems thinking. Her father, an accomplished engineer in nano-electronics and VLSI design, further influenced the analytical mindset that would later become central to her medical career.

That intellectual foundation became especially relevant in 2008, while practicing in Nashua, New Hampshire. Patients repeatedly asked why managing their weight seemed so difficult despite their efforts. The questions exposed a gap between conventional explanations and the biological complexity patients were experiencing.

That moment redirected Srivastava's professional focus toward obesity and metabolic medicine.

Moving Beyond a Lifestyle-Only Model

Srivastava's approach treats obesity as a biologically regulated chronic condition rather than simply a consequence of individual behavior. Her clinical work encompasses adults, children, and patients with rare genetic forms of obesity, providing a broad perspective on the mechanisms influencing weight and metabolic health.

This philosophy supports a more individualized model of care—one that considers neurohormonal, genetic, and metabolic factors alongside patient circumstances.

Her work also extends beyond clinical practice. As a contributor and execution lead on international landmark obesity and metabolism drug trials, she has been involved in protocol execution, patient adherence and retention, and data integrity. According to the source material, these efforts helped de-risk more than $400 million in enterprise asset value across multi-billion-dollar therapeutic portfolios.

AI as the Next Layer of Precision Healthcare

Artificial intelligence represents another major dimension of Srivastava's healthcare strategy. Through an industry-funded initiative exceeding $1 million, she is leading clinical development of an AI-enabled adherence and prescribing platform intended to improve real-world outcomes for advanced obesity therapies.

Predictive modeling, particularly around GLP-1 therapies, offers the potential to move treatment decisions toward patient-specific pathways rather than repeated trial and adjustment.

The broader objective is equally important: building systems capable of extending sophisticated healthcare beyond traditionally well-served populations. By combining clinical expertise with data-driven tools, healthcare could become more predictive, coordinated, and accessible.

Designing Healthcare for a Global Reality

Innovation, however, cannot be separated from healthcare economics and policy. Access challenges differ considerably across countries. Insurance and cost barriers shape care in the United States, affordability remains a major issue in India, while universal systems such as those in the United Kingdom and Canada face resource and waiting-time pressures.

Srivastava's perspective emphasizes adaptability rather than a single universal solution. Technology, policy, clinical evidence, and patient safety must evolve together.

Her leadership philosophy similarly combines ambition with execution. Passion, inspiration, and sustained effort form the foundation of her approach to building teams and scaling initiatives.

A More Human Definition of Innovation

For Srivastava, healthcare transformation is not solely about sophisticated technology or scientific advancement. Personal relationships, balance, and purpose remain important measures of meaningful success.

Her experiences have reinforced a belief that future healthcare leaders need multidisciplinary skills, strong boundaries, effective time management, and the confidence to challenge established thinking. Storytelling and public communication also matter, particularly in reshaping perceptions of obesity and replacing stigma with greater scientific understanding and empathy.

The emerging healthcare model she represents is therefore broader than a new treatment or digital platform. It is an interconnected ecosystem where clinicians, researchers, biopharma organizations, technologists, policymakers, and patients contribute to a more continuous model of health management.

Looking Ahead

As medicine moves toward predictive analytics, precision therapeutics, and lifelong health management, Srivastava's career illustrates the value of crossing disciplinary boundaries. Her work brings together clinical science, computational thinking, therapeutic development, and human-centered leadership—an approach that could help define how metabolic health is addressed at scale.

Read the full article on: Gitanjali Srivastava or explore more about The 2026 Power List: Leaders Driving Global Impact.